



## Ban on Fixed-dose Combination Drugs

### Why in news?

\n\n

The Drug Technical Advisory Board has recommended banning 343 “irrational” fixed-dose combination (FDC) drugs

\n\n

### What are FDC drugs?

\n\n

\n

- An FDC drug is one that contains two or more active ingredients combined in a fixed dose to form a single drug.
- Several cough syrups, painkillers and dermatological drugs in India are FDCs.
- Some are marketed with licenses approved only by state regulatory agencies instead of the Drug Controller General of India.
- These FDCs could be irrational and unsafe for consumption, with potential health risks.
- Rampant use of FDCs has allowed antibiotic resistance to assume threatening proportions in India.
- However, not all FDCs are unsafe as some are crucial to treat chronic illnesses like diabetes and HIV.

\n

\n\n

### How did the issue evolve?

\n\n

\n

- **Ban** - In 2016, the Ministry of Health and Family Welfare had implemented a ban on 349 FDCs.

\n

- It included popular brands like Saridon, Corex, D Cold Total, and Vicks Action 500 Extra, etc.

\n

- The government says there are enough single drug alternatives that are safer and effective.

\n

- **Committee** - The ban was based on recommendations of the Chandrakant Kokate committee.

\n

- It said FDCs are "unsafe" and "irrational" for consumption, posing health risks.

\n

- **Court** - On pharma companies challenging the ban, the matter was taken to the Supreme Court.

\n

- Drug makers argued that the statutory bodies on drug regulations were not consulted before the ban.

\n

- Eventually, the Supreme Court referred the matter to the Drug Technical Advisory Board (DTAB).

\n

- It directed the DTAB to make a fresh review of the issue with fixed-dose combination drugs.

\n

\n\n

## What are DTAB's findings?

\n\n

\n

- Most of the pharma companies had not generated safety and efficacy data of their own for their FDCs.

\n

- Almost 95% of the appellants failed to prove safety, rationality and compatibility of these FDCs.

\n

- The indications for which these FDCs were mentioned were too "vague" and not "as per treatment guidelines."

\n

- For most FDCs, their use would lead to "unnecessary over use".

\n

- So, patients would be exposed to risk of multiple ingredients, when actually one would suffice.

\n

- Over the years, India has become a dumping ground for irrational FDCs that are not approved in other countries.

\n

\n\n

\n

- **Decision** - The DTAB in a meeting held recently re-inforced the ban on 343 of the 349 drugs.

\n

- It, however, felt restricted use could be allowed for six FDCs.

\n

- The DTAB would forward its report to the health ministry soon.

\n

\n\n

## What are the implications?

\n\n

\n

- The market size of the banned drugs is estimated to be around Rs 20-22 billion.

\n

- The ban, if comes into force, will thus impact the country's top drug-makers.

\n

- These FDCs roughly contribute to 1.8% of the overall domestic drug market.

\n

- The FDC segment is already on a slower growth rate (4.7% in June) compared to the rest of the domestic drug market (8.6%).

\n

- These 343 FDCs are only a small portion of the FDCs that are sold in the country.

\n

- The bigger uncertainty would be the additional 944 FDCs that were identified by the Kokate committee as being irrational.

\n

- The DTAB may look at these products now, and the coverage of the ban is expected to expand.

\n

\n\n

\n\n

**Source: Economic Times, Business Standard**

\n\n

\n\n

### **Quick Fact**

\n\n

### **Drugs Technical Advisory Board**

\n\n

- DTAB is the apex body to decide on technical matters related to drugs in the country.
- It is constituted as per the Drugs and Cosmetics Act, 1940.
- It functions as part of the Central Drugs Standard Control Organization (CDSCO) in the Ministry of Health and Family Welfare.

\n



**IAS PARLIAMENT**  
*Information is Empowering*  
A Shankar IAS Academy Initiative